ArticleNuclear medicine and biology2016
Trithiols and their arsenic compounds for potential use in diagnostic and therapeutic radiopharmaceuticals.
Article in Nuclear medicine and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 39 citations in OpenAlex.
- The Application of Radiolabeled Mesoporous Silica Nanoparticles in Molecular Imaging.Molecules (Basel, Switzerland) · 2026Review
- Coordination Chemistry of Emerging Meitner-Auger Electron-Emitting Radiometals for Targeted Radionuclide Therapy.Coordination chemistry reviews · 2025Article
- Towards the Stable Chelation of Radioantimony(V) for Targeted Auger Theranostics.Angewandte Chemie (International ed. in English) · 2025Article
- Synthesis and structural characterization of the heavy tricysteinylpnictines, models of protein-bound As(III), Sb(III), and Bi(III).Dalton transactions (Cambridge, England : 2003) · 2024Article
- Radiochemistry: A Hot Field with Opportunities for Cool Chemistry.ACS central science · 2023Review
- Facile transmetallation of [SbRSC advances · 2022Article
- A Third Generation Potentially Bifunctional Trithiol Chelate, ItsInorganic chemistry · 2021Article
- Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119Current radiopharmaceuticals · 2021Article
- Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders-An Update.Cancers · 2020Review
- Self-assembly of reversed bilayer vesicles through pnictogen bonding: water-stable supramolecular nanocontainers for organic solvents.Chemical science · 2020Article
- The Impact of Positron Range on PET Resolution, Evaluated with Phantoms and PHITS Monte Carlo Simulations for Conventional and Non-conventional Radionuclides.Molecular imaging and biology · 2020Article
- PET radiometals for antibody labeling.Journal of labelled compounds & radiopharmaceuticals · 2018Review
- Intrinsic and Stable Conjugation of Thiolated Mesoporous Silica Nanoparticles with Radioarsenic.ACS applied materials & interfaces · 2017Article
- Chromatographic separation of germanium and arsenic for the production of high purity (77)As.Journal of chromatography. A · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
introductionArsenic-72 ((72)As; 2.49MeV β(+), 26h) and (77)As (0.683MeV β(-), 38.8h) have nuclear properties useful for positron emission tomography (PET) and radiotherapy applications, respectively. Their half-lives are sufficiently long for targeting tumors with antibodies, as well as peptides. Potential radiopharmaceuticals based on radioarsenic require development of suitable bifunctional chelates for stable conjugation of arsenic to vectors under in vivo conditions at high dilution.
methodsThe thiophilic nature of arsenic led to the synthesis and characterization of a simple trithiol ligand and its arsenic complex, and radiolabeling studies at the no carrier added (NCA) (77)As level.
results(1)H- and (13)C-NMR spectroscopy, electrospray ionization mass spectrometry (ESI-MS), and single crystal X-ray diffraction were used to characterize the trithiol ligand and its arsenic(III) complex. Radiotracer studies with no carrier added (NCA) (77)As resulted in high radiolabeling yields (>96%) with high in vitro stability.
conclusionsThe high yield and stability of a single NCA (77)As trithiol complex indicates that this framework is suitable for developing matched pair agents for non-invasive in vivo PET imaging and radiotherapy of tumors with (72,77)As. This is the first reported chelate developed for NCA radioarsenic and studies are underway for developing a trithiol bifunctional chelate conjugated to a targeting vector, such as a peptide or monoclonal antibody.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.